#1 Clinical Trials Search in Europe

Dasiglucagon

Dasiglucagon is an innovative drug being studied in clinical trials for its potential to treat hypoglycemia (low blood sugar) in people with diabetes and congenital hyperinsulinism. This article summarizes key findings from recent clinical trials evaluating dasiglucagon’s safety and effectiveness compared to existing treatments. The trials suggest dasiglucagon may offer advantages in raising blood sugar levels quickly and conveniently in emergency situations.

Table of Contents

What is Dasiglucagon?

Dasiglucagon is a new medication that belongs to a class of drugs called glucagon analogs. It is also known by the names ZP4207 and Zegalogue[1][2]. Dasiglucagon is designed to mimic the effects of glucagon, a hormone naturally produced by the body that helps raise blood sugar levels[3].

Unlike traditional glucagon, which can be difficult to prepare and use, dasiglucagon comes in a ready-to-use liquid form. This makes it easier and quicker to administer in emergency situations[3].

What Conditions Does Dasiglucagon Treat?

Dasiglucagon is primarily used to treat or prevent several conditions related to blood sugar levels:

  • Severe Hypoglycemia: This is a dangerous condition where blood sugar levels drop too low in people with diabetes. Dasiglucagon can quickly raise blood sugar levels in these emergency situations[4].
  • Type 1 Diabetes: While not a cure for diabetes, dasiglucagon can help manage dangerous low blood sugar episodes in people with type 1 diabetes[5].
  • Congenital Hyperinsulinism: This is a rare genetic condition where the body produces too much insulin, leading to frequent episodes of low blood sugar. Dasiglucagon is being studied as a potential treatment for children with this condition[6].
  • Post-Bariatric Hypoglycemia: Some people who have had gastric bypass surgery experience episodes of low blood sugar. Dasiglucagon is being investigated as a treatment for this condition[7].

How Does Dasiglucagon Work?

Dasiglucagon works by mimicking the action of glucagon in the body. When blood sugar levels are too low, dasiglucagon stimulates the liver to release stored glucose (sugar) into the bloodstream. This helps to quickly raise blood sugar levels and alleviate symptoms of hypoglycemia[3].

In clinical trials, dasiglucagon has been shown to raise blood sugar levels within 10-15 minutes after administration[4]. This rapid action is crucial in emergency situations where quick treatment of severe hypoglycemia is necessary.

How is Dasiglucagon Administered?

Dasiglucagon is typically administered as a subcutaneous (under the skin) injection. It comes in several forms:

  • Pre-filled syringe[2]
  • Auto-injector pen[5]
  • Continuous infusion pump (for certain conditions like congenital hyperinsulinism)[8]

The dose of dasiglucagon may vary depending on the condition being treated and the patient’s age. For example, in some trials, adults received a 0.6 mg dose, while children received lower doses of 0.3 mg or 0.6 mg based on their age and weight[2].

Clinical Trials and Research

Dasiglucagon has been the subject of numerous clinical trials to evaluate its safety and effectiveness. Some key findings from these trials include:

  • Effectiveness in treating severe hypoglycemia in adults with type 1 diabetes[4]
  • Potential use in automated insulin delivery systems for preventing hypoglycemia in people with type 1 diabetes[5]
  • Promising results in treating children with congenital hyperinsulinism[8]
  • Investigation of its use in treating post-bariatric hypoglycemia[7]

These trials have helped establish the effectiveness of dasiglucagon in various scenarios and patient populations.

Safety and Side Effects

Like all medications, dasiglucagon can cause side effects. Common side effects reported in clinical trials include:

  • Nausea
  • Vomiting
  • Headache
  • Diarrhea
  • Injection site reactions (such as pain or redness)[3]

Most side effects were reported to be mild to moderate in severity. However, as with any medication, it’s important to discuss potential risks and benefits with your healthcare provider.

Researchers have also studied the potential for dasiglucagon to cause an immune response in the body. Some patients may develop antibodies to the medication, but the clinical significance of this is still being studied[1].

Overall, dasiglucagon represents a promising new treatment option for various conditions related to low blood sugar. Its rapid action and easy-to-use formulation make it a valuable tool in managing hypoglycemia and related conditions. As research continues, we may see expanded uses for this medication in the future.

Aspect Details
Primary Use Treatment of severe hypoglycemia in diabetes patients
Other Potential Uses Management of congenital hyperinsulinism, post-bariatric hypoglycemia
Administration Subcutaneous injection, also tested as intravenous and continuous infusion
Key Advantages Fast-acting, ready-to-use liquid formulation
Primary Outcome Measure Time to plasma glucose recovery
Common Side Effects Nausea, vomiting, headache, injection site reactions
Patient Populations Studied Adults and children with T1DM, children with congenital hyperinsulinism
Comparison to Standard Treatment Potentially faster and more convenient than traditional glucagon

FAQ

  • What is dasiglucagon? Dasiglucagon is a stable peptide analog of human glucagon, designed to mimic the effects of glucagon in raising blood sugar levels. It comes in a ready-to-use liquid form and is being developed to treat severe hypoglycemia in people with diabetes.
  • How is dasiglucagon administered? In the clinical trials, dasiglucagon was administered as a subcutaneous (under the skin) injection, typically in the buttocks or arm. Some trials also tested intravenous administration and continuous infusion via pump.
  • What conditions is dasiglucagon being studied for? Dasiglucagon is primarily being studied for treating severe hypoglycemia in people with type 1 diabetes. It's also being investigated for managing congenital hyperinsulinism in children and post-bariatric hypoglycemia in adults.
  • How does dasiglucagon compare to existing glucagon treatments? Clinical trials suggest dasiglucagon may work faster than traditional glucagon to raise blood sugar levels. It also comes in a ready-to-use liquid form, which could be more convenient in emergency situations compared to glucagon kits that require mixing.
  • What are the main side effects of dasiglucagon seen in trials? Common side effects reported in trials included nausea, vomiting, headache, and injection site reactions. Most side effects were mild to moderate. As with any medication, patients should discuss potential risks and benefits with their doctor.

Ongoing Clinical Trials on Dasiglucagon

  • Using glucagon and automated insulin delivery to prevent low blood sugar during exercise in adults with type 1 diabetes

    Recruiting

    1 1 1 1
    Investigated drugs:
    Denmark

  • Long-term Safety Study of Dasiglucagon for Children with Congenital Hyperinsulinism

    Not recruiting

    1 1 1
    Investigated drugs:
    Germany

Glossary

  • Congenital Hyperinsulinism (CHI): A rare genetic disorder where the pancreas produces too much insulin, leading to frequent episodes of low blood sugar (hypoglycemia) in infants and children.
  • Dasiglucagon: A stable peptide analog of human glucagon, designed to raise blood sugar levels quickly. It's being developed as a treatment for severe hypoglycemia and other conditions.
  • Glucagon: A hormone that raises blood sugar levels. It's used as an emergency treatment for severe hypoglycemia in people with diabetes.
  • Hypoglycemia: A condition where blood sugar levels drop below normal, which can be dangerous if severe. Common in people with diabetes who use insulin or certain medications.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and the relationship between drug concentration and effect.
  • Pharmacokinetics (PK): The study of how the body processes a drug, including its absorption, distribution, metabolism, and excretion.
  • Plasma Glucose: The amount of glucose (sugar) present in the blood plasma. It's a key measure of blood sugar control.
  • Subcutaneous (SC) Injection: An injection given into the fatty tissue just beneath the skin. This is how dasiglucagon is typically administered in the clinical trials.
  • Type 1 Diabetes Mellitus (T1DM): An autoimmune condition where the pancreas produces little or no insulin, requiring lifelong insulin therapy and careful blood sugar management.

References

  1. https://clinicaltrials.gov/study/NCT03216226
  2. https://clinicaltrials.gov/study/NCT05378672
  3. https://clinicaltrials.gov/study/NCT03735225
  4. https://clinicaltrials.gov/study/NCT03688711
  5. https://clinicaltrials.gov/study/NCT04764968
  6. https://clinicaltrials.eu/trial/long-term-safety-study-of-dasiglucagon-for-children-with-congenital-hyperinsulinism/
  7. https://clinicaltrials.gov/study/NCT04824872
  8. https://clinicaltrials.gov/study/NCT04172441